Eyeworld Daily News

59 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, New Orleans 2016 Take a tour of the Laura Plantation or Oak Alley Plantation leaving from New Orleans. Gray Line also offers a number of other tour options around New Orleans, including swamp tours, walking tours, evening tours, cruises, and combination tours. The Old River Road Plantation Adventure 2041 Canal Street 866-671-8687 www.plantationadventure.com Choose from a variety of tour packages to see different locations. Among the stops are Oak Alley Plantation, San Francisco Plantation, Laura Plantation, and Evergreen Plantation. Several of the tour pair- ings include the option for a tour of the cypress swamp and wetlands. This tour company also offers a New Orleans city tour, cruises, and other swamp tours. Destrehan Plantation 13034 River Road Destrehan, Louisiana 985-764-9315 www.destrehanplantation.org Located just over 20 miles from New Orleans, this historic plantation was built in the late 1700s. The "Greek revival" house formerly produced sugar. Tours of the plantation are held daily from 9:00 a.m. to 4:00 p.m., with an $18 admission fee for adults. Laura Plantation 2247 Highway 18 Vacherie, Louisiana 225-265-7690 www.lauraplantation.com This Creole plantation is a historic site that was a sugar plantation. Take a tour of the house, plantation, slave cabins, and gardens. Admission is $20 for adults, and tours begin daily at 10:00 a.m. and end at 4:00 p.m. Laura Plantation is just about an hour from New Orleans. Oak Alley Plantation 3645 Highway 18 Vacherie, Louisiana 225-265-2151 www.oakalleyplantation.com Named for its alley of oak trees, the plantation was built in 1837. It has been used in a number of modern day media, including as a setting for the film Interview with the Vampire. From March through October, the plantation is open from 9:00 a.m. to 5:00 p.m. daily. Tours of the grounds and house are available for $20 for adults. Oak Alley is just under an hour from New Orleans. EW INDICATIONS AND USAGE PROLENSA ® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-infl ammatory drug (NSAID) indicated for the treatment of postoperative infl ammation and reduction of ocular pain in patients who have undergone cataract surgery. IMPORTANT SAFETY INFORMATION ABOUT PROLENSA ® • PROLENSA ® contains sodium sulfi te, a sulfi te that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfi te sensitivity in the general population is unknown and probably low. Sulfi te sensitivity is seen more frequently in asthmatic than in non-asthmatic people. • All topical nonsteroidal anti-infl ammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs. • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. • PROLENSA ® should not be instilled while wearing contact lenses. The preservative in PROLENSA ® , benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA ® . • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber infl ammation, foreign body sensation, eye pain, photophobia, and blurred vision. Please see brief summary of full Prescribing Information for PROLENSA ® on adjacent page. References: 1. PROLENSA Prescribing Information, April 2013. 2. Data on fi le, Bausch & Lomb Incorporated. 3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. PROLENSA is a registered trademark of Bausch & Lomb Incorporated or its affi liates. © Bausch & Lomb Incorporated. All rights reserved. Printed in USA. PRA.0188.USA.15 The PROLENSA ® Effect POWERED FOR PENETRATION Advanced Formulation to Facilitate Corneal Penetration 1-3 pH e ffect Hal og en a ti on e ffect PROLENSA ® delivers potency and corneal penetration with QD dosing at a low concentration 1-3

• Cover